Literature DB >> 32936677

Long-term Results of Arthroscopic Matrix-Assisted Autologous Chondrocyte Transplantation: A Prospective Follow-up at 15 Years.

Luca Andriolo1, Davide Reale1, Alessandro Di Martino1, Roberto De Filippis1, Andrea Sessa2, Stefano Zaffagnini1, Giuseppe Filardo3.   

Abstract

BACKGROUND: Matrix-assisted autologous chondrocyte transplantation (MACT) procedures have been developed to overcome some of the limits of first-generation autologous chondrocyte implantation. However, while good autologous chondrocyte implantation results have been documented over time, data are scarce on the long-term MACT results.
PURPOSE: To evaluate long-term clinical results of a large cohort of patients treated with hyaluronic acid-based MACT for articular cartilage defects of the knee. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: A long-term evaluation of 113 patients was performed (91 men, 22 women; mean ± SD age, 29.0 ± 10.6 years) for 115 knees affected by chondral and osteochondral lesions of the femoral condyles and trochlea. Of these, 61 knees had undergone previous surgery, while other procedures were combined during the same operation in 48 knees. These patients were prospectively evaluated before surgery and at 2, 5, and 10 years after surgery, as well as at a final mean follow-up of 15 years (range, 12-18 years), with various clinical scores: International Knee Documentation Committee (IKDC), EuroQol visual analog scale (EQ-VAS), and Tegner. Both surgical and clinical failures were documented.
RESULTS: The IKDC subjective score increased from the basal level of 39.9 ± 14.6 (mean ± SD) to 77.3 ± 20.5 (P < .0005) at 2 years; results remained stable up to the 15-year follow-up (76.9 ± 20.5). EQ-VAS and Tegner scores showed a statistically significant improvement up to 10 years, with a further significant improvement at the final follow-up. A failure rate of 15.0% was documented, which increased to 21.7% when clinical failures were also considered. A worse outcome was found for older age (P < .0005), female sex (P = .002), degenerative lesions (P < .0005), longer duration of symptoms (P = .005), and previous surgery (P < .0005).
CONCLUSION: Arthroscopic MACT offered good and long-lasting results that were stable over time and resulted in a limited number of failures and reinterventions for up to 15 years of follow-up. Several factors were identified as having a prognostic value: a worse outcome could be expected in older patients, female patients, those affected by lesions with a degenerative cause, those having a longer duration of symptoms, and patients who underwent previous surgery.

Entities:  

Keywords:  arthroscopic MACT; cartilage; knee; long-term results; prognostic factors

Year:  2020        PMID: 32936677     DOI: 10.1177/0363546520949849

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  10 in total

1.  Chitosan based scaffold applied in patellar cartilage lesions showed positive clinical and MRI results at minimum 2 years of follow up.

Authors:  Alberto Poggi; Alessandro Di Martino; Luca Andriolo; Davide Reale; Giuseppe Filardo; Elizaveta Kon; Stefano Zaffagnini
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-06-09       Impact factor: 4.342

2.  Report of a clinical and laboratory management of cell therapy for knee cartilage in the face of mycoplasma contamination.

Authors:  Alessandro Rozim Zorzi; Eliane Antonioli; Juliana Aparecida Preto de Godoy; Oswaldo Keith Okamoto; Andrea Tiemi Kondo; José Mauro Kutner; Camila Cohen Kaleka; Moisés Cohen; Mario Ferretti
Journal:  Einstein (Sao Paulo)       Date:  2022-06-17

3.  Progenitor Cells in Healthy and Osteoarthritic Human Cartilage Have Extensive Culture Expansion Capacity while Retaining Chondrogenic Properties.

Authors:  M Rikkers; J V Korpershoek; R Levato; J Malda; L A Vonk
Journal:  Cartilage       Date:  2021-11-20       Impact factor: 3.117

4.  Cell therapies for chondral defects of the talus: a systematic review.

Authors:  Filippo Migliorini; Jörg Eschweiler; Christian Goetze; Torsten Pastor; Riccardo Giorgino; Frank Hildebrand; Nicola Maffulli
Journal:  J Orthop Surg Res       Date:  2022-06-11       Impact factor: 2.677

5.  Matrix-assisted autologous chondrocyte transplantation for treatment of focal chondral lesions in the knee: the Hospital Israelita Albert Einstein experience.

Authors:  Alessandro Rozim Zorzi; Eliane Antonioli; Camila Cohen Kaleka; Moisés Cohen; Juliana Aparecida Preto de Godoy; Andrea Tiemi Kondo; José Mauro Kutner; Mario Lenza; Mario Ferretti
Journal:  Einstein (Sao Paulo)       Date:  2022-05-06

6.  Comment on "Twenty-two-year outcome of cartilage repair surgery by perichondrium transplantation" Maarten P. F. Janssen, et al.

Authors:  Luca Andriolo; Angelo Boffa; Giuseppe Filardo
Journal:  Cartilage       Date:  2020-12-24       Impact factor: 3.117

Review 7.  Influence of the Mechanical Environment on the Regeneration of Osteochondral Defects.

Authors:  Sarah Davis; Marta Roldo; Gordon Blunn; Gianluca Tozzi; Tosca Roncada
Journal:  Front Bioeng Biotechnol       Date:  2021-01-27

8.  Hydrogel-based autologous chondrocyte implantation leads to subjective improvement levels comparable to scaffold based autologous chondrocyte implantation.

Authors:  Thomas Richard Niethammer; Felix Uhlemann; Anja Zhang; Martin Holzgruber; Ferdinand Wagner; Peter Ernst Müller
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-02-28       Impact factor: 4.114

9.  Global Variation in Studies of Articular Cartilage Procedures of the Knee: A Systematic Review.

Authors:  R Garrett Steinmetz; J Jared Guth; Matthew J Matava; Matthew V Smith; Robert H Brophy
Journal:  Cartilage       Date:  2022 Apr-Jun       Impact factor: 3.117

Review 10.  Cell-based treatment options facilitate regeneration of cartilage, ligaments and meniscus in demanding conditions of the knee by a whole joint approach.

Authors:  Peter Angele; Denitsa Docheva; Girish Pattappa; Johannes Zellner
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-03-05       Impact factor: 4.342

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.